Feedback PLC Collaboration with Princess Alexandra Hospital, AU
28 April 2015 - 8:01AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
28 April 2015
28 April 2015
Feedback plc
("Feedback" or the "Company")
Collaboration with the Princess Alexandra Hospital (PAH),
Australia
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce that it is undertaking a study using its
TexRAD research product with the Diagnostic Radiology department at
the Princess Alexandra Hospital ("PAH") in Brisbane, Australia to
assess the potential for clinical workflow integration for TexRAD
quantitative computed tomography ("CT") specifically focused on
non-small cell lung cancer.
The study will be led by Prof. Ken Miles (Senior Medical Officer
in the Diagnostic Radiology department of PAH). Prof. Miles is also
a Professorial Research Associate in the Institute of Nuclear
Medicine, University College London, UK. Prof. Miles has an
international reputation in functional imaging of tumours, ranging
from the development of new techniques through to demonstrating
cost-effectiveness. For example he has been one of the pioneers of
CT perfusion (blood-flow) and CT texture (heterogeneity) analysis
technologies.
Prof. Ken Miles commented:
"TexRAD as research software has been used to investigate lung
cancer on CT where it has been shown to be associated with
underlying tumour biology and has the potential to be an
independent prognostic marker. Preliminary studies have also
demonstrated potential clinical applications for TexRAD analysis to
assist treatment decisions and optimise lung cancer patient
management in a cost-effective manner. We hope this study will
demonstrate that TexRAD could be incorporated into the routine
radiological workflow."
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer
of the Company's subsidiaries TexRAD Ltd & Cambridge Computed
Imaging Ltd commented:
"Prof. Ken Miles is one of the top functional imaging academics,
dual trained in radiology and nuclear medicine and we are delighted
that he will be leading the very first landmark study in evaluating
potential clinical implementation with our TexRAD software focused
on lung cancer. Working with Princess Alexandra Hospital in
Brisbane will enhance our TexRAD research collaborator base with
the addition of a key site in this new geographical region."
For further information contact:
Feedback plc Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser Tel: 020 7628
and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd (Joint Tel: 020 7469
Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'. TexRAD is
manufactured under licence by the ISO 13485 certified company
Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More
information is available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPKODDABKDPQB
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024